COMPARISON
Lixisenatide vs Semaglutide
6 attributes held for at least one of the two. 5 differ. Each value carries the register it came from and the date that register was read.
Answer
Lixisenatide is authorised or registered in 8 and Semaglutide in 10 of the 10 registers read. Lixisenatide: No trial states a phase. Semaglutide: highest phase Phase 4 (after approval). 4 registered trials include both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Lixisenatide | Semaglutide | |
|---|---|---|
| Registered trials differs | 75 clinicaltrials.gov · 2026-10-03 | 861 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | FDA-approved: Soliqua 100/33 openfda · 2026-10-03T17:23:44.062Z | FDA-approved: OZEMPIC openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation | Authorised ema · 2026-10-03 | Authorised ema · 2026-10-03 |
| EU authorised on differs | 2017-01-11 ema · 2026-10-03 | 2018-02-08 ema · 2026-10-03 |
| EU withdrawn on differs | 2024-08-27 ema · 2026-10-03 | Not checked no record of "withdrawnOn" for semaglutide |
| ATC code differs | A10AE54 ema · 2026-10-03 | A10BJ06 ema · 2026-10-03 |
SIDE EFFECTS
Most common side effects, each beside its own placebo
| Side effect | Lixisenatide | placebo | Semaglutide | placebo |
|---|---|---|---|---|
| Nausea | 24.8% | 6.5% | 19.5% | 4.5% |
| Vomiting | 10.3% | 2.6% | 8.6% | 1.6% |
| Diarrhoea | 10.1% | 8.1% | 11.8% | 4.5% |
| Headache | 9.6% | 6.8% | 4.0% | 2.1% |
| Nasopharyngitis | 9.1% | 9.0% | 7.5% | 6.1% |
| Hypoglycaemia | 18.4% | 16.4% | - | - |
| Dizziness | 8.3% | 6.3% | - | - |
| Hypertension | 4.6% | 4.9% | - | - |
| Influenza | 4.4% | 2.4% | - | - |
| Angina pectoris | 4.3% | 5.5% | - | - |
| COVID-19 | - | - | 17.0% | 17.8% |
| Constipation | - | - | 8.9% | 2.8% |
| Decreased appetite | - | - | 6.3% | 1.3% |
| Dyspepsia | - | - | 5.3% | 1.2% |
| Upper respiratory tract infection | - | - | 2.7% | 1.9% |
Trial register Lixisenatide: 11 placebo-controlled trials; Semaglutide: 50. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Lixisenatide side effects · Semaglutide side effects
LEGAL STATUS
Approval in each country read
| Country | Lixisenatide | Semaglutide | Register |
|---|---|---|---|
| United States | FDA-approved | FDA-approved | Regulator FDA |
| European Union | Authorised | Authorised | Regulator EMA |
| United Kingdom | Not on the register | Authorised | Regulator MHRA |
| Canada | Authorised | Authorised | Regulator Health Canada |
| Australia | Status unknown | Registered | TGA |
| Switzerland | Authorised | Authorised | Regulator Swissmedic |
| Brazil | Registado | Registado | Regulator ANVISA |
| Serbia | Authorised | Authorised | Regulator ALIMS |
| Singapore | Registered | Registered | Regulator HSA |
| Turkey | Ruhsatli | Ruhsatli | Regulator TITCK |
HEAD TO HEAD
4 registered trials include both
| NCT05220917 | Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study ACTIVE_NOT_RECRUITING · updated 2026-08-13 |
|---|---|
| NCT07188545 | Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Rea ACTIVE_NOT_RECRUITING · updated 2025-09-23 |
| NCT06449235 | Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh UNKNOWN · updated 2024-07-16 |
| NCT05136287 | SEMAGLUTIDE VERSUS GLP-1 RECEPTOR AGONISTS. EFFECTIVENESS , SAFETY AND QUALITY OF LIFE IN PATIENTS WITH DIABETES MELLITUS 2. OBSERVATIONAL, PROSPECTIVE AND MULT COMPLETED · updated 2024-02-28 |
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.